Veradermics is a clinical-stage biopharmaceutical company with a single lead candidate: VDPHL01, an oral extended-release formulation of minoxidil for the treatment of pattern hair loss in men and women. The core innovation is a proprietary hydrogel tablet that releases minoxidil gradually over 12–24 hours, designed to keep plasma concentrations above the hair growth threshold while staying below the cardiac activity threshold — a limitation that constrains off-label use of immediate-release oral minoxidil at higher doses. If approved, VDPHL01 would be the first FDA-approved oral minoxidil product and the first approved oral treatment for female pattern hair loss. Veradermics is running three registration-directed Phase 2/3 and Phase 3 trials under the FDA's 505(b)(2) pathway, with topline data from two fully-enrolled male trials expected in 2026 and a female trial still enrolling. The company plans to commercialize VDPHL01 as a cash-pay prescription product, bypassing insurance entirely — consistent with the aesthetics market — and targeting a concentrated base of roughly 7,000 high-volume prescribers with a lean sales force, supplemented by DTC digital advertising and telehealth platforms. Pattern hair loss is a chronic, lifelong condition, supporting recurring revenue per patient. Veradermics has no approved products or commercial revenue and funds operations through equity capital.